| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 101901 | 100 ug | $50 | ||
| 101902 | 500 ug | $150 |
| Clone | FN50 |
|---|---|
| Application | FC, IHC-F |
| Reactivity | Human |
| Format | Purified |
| Target Name | CD69, Very Early Activation Antigent (VEA) |
| Isotype | Mouse IgG1 |
| Antibody Type | Monoclonal |
| Regulatory Status | RUO |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide |
| Protein Concentration | 0.5 mg/mL |
| Storage&Handling | The antibody solution should be stored between 2°C and 8°C |
CD69 (also known as CLEC2C, VEA, AIM, EA1, MLR3, gp34/28) is a type II transmembrane C-type lectin glycoprotein that forms a ~60 kDa disulfide-linked homodimer. The mature human protein consists of a 40-amino-acid cytoplasmic domain, a 21-amino-acid transmembrane segment, and a 138-amino-acid extracellular domain containing a C-type lectin domain, sharing ~57% sequence identity with mouse and rat CD69. CD69 is rapidly upregulated on activated immune cells, including CD4⁺ and CD8⁺ T cells, NK cells, NKT cells, γδ T cells, B cells, dendritic cells, neutrophils, and a subset of thymocytes and platelets. It functions as an early activation marker, mediates T cell differentiation, immune cell trafficking, and homing of CD4⁺ T cells and plasmablasts to bone marrow, while inhibiting migration of dermal dendritic cells to lymph nodes.
Have a product or application question? Consult our FAQs or contact us.
